Compare Equinor ASA (EQNR) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Johnson & Johnson — how do they compare? Equinor ASA trades at $40.98 (market cap $97.58B), while Johnson & Johnson trades at $260.7 (market cap $626.09B). The key difference: Johnson & Johnson is far larger — about 6.4× Equinor ASA's market cap, and Equinor ASA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EQNR | JNJ | |
|---|---|---|
Market Cap | $97.58B | $626.09B |
Sector | Energy | Health |
52-Week High | $42.40 | $267.24 |
52-Week Low | $22.41 | $172.78 |
Enterprise Value | $106.28B | $654.37B |
Dividend Yield | 3.81% | 2.06% |
Volume | — | 6,156,228 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $40.92, down slightly by 0.17% on the day, with strong technical momentum showing a bullish moving average signal. The company delivered mixed Q2 2026 earnings with a revenue beat but EPS miss, while maintaining robust cash flow generation and shareholder returns through dividends and buybacks. Recent news highlights strong quarterly performance driven by higher energy prices and production growth.
EQNR presents a compelling value case with attractive valuation multiples (P/E 11.09, EV/EBITDA 2.3) and solid profitability metrics (ROE 21.32%). However, declining profit margins from 19.29% in 2022 to 4.76% in 2025 and analyst caution (56.53% hold rating) suggest balanced risk-reward. The stock offers income potential with consistent dividends amid energy market volatility.
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
